NASDAQ:PAVM - PAVmed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.0864 +0.05 (+4.82 %)
(As of 12/18/2018 12:53 PM ET)
Previous Close$1.04
Today's Range$1.04 - $1.10
52-Week Range$0.87 - $3.98
Volume95,319 shs
Average Volume135,795 shs
Market Capitalization$28.40 million
P/E Ratio-2.09
Dividend YieldN/A
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

Receive PAVM News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Current SymbolNASDAQ:PAVM
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio1.61
Quick Ratio1.61


Trailing P/E Ratio-2.09
Forward P/E Ratio-3.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.22) per share
Price / Book-4.94


EPS (Most Recent Fiscal Year)($0.52)
Net Income$-9,510,000.00
Net MarginsN/A
Return on Equity-3,311.56%
Return on Assets-138.83%


Outstanding Shares26,540,000
Market Cap$28.40 million
OptionableNot Optionable

PAVmed (NASDAQ:PAVM) Frequently Asked Questions

What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

How were PAVmed's earnings last quarter?

PAVmed Inc (NASDAQ:PAVM) announced its quarterly earnings results on Thursday, November, 15th. The company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.04. View PAVmed's Earnings History.

When is PAVmed's next earnings date?

PAVmed is scheduled to release their next quarterly earnings announcement on Wednesday, April 10th 2019. View Earnings Estimates for PAVmed.

What price target have analysts set for PAVM?

1 Wall Street analysts have issued twelve-month price targets for PAVmed's stock. Their forecasts range from $5.00 to $5.00. On average, they expect PAVmed's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 370.1% from the stock's current price. View Analyst Price Targets for PAVmed.

What is the consensus analysts' recommendation for PAVmed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PAVmed.

Has PAVmed been receiving favorable news coverage?

News stories about PAVM stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PAVmed earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the next few days.

Who are some of PAVmed's key competitors?

Who are PAVmed's key executives?

PAVmed's management team includes the folowing people:
  • Dr. Lishan Aklog M.D., Chairman & CEO (Age 52)
  • Mr. Dennis M. McGrath CPA, Exec. VP, CFO & Sec. (Age 61)
  • Dr. Brian J. deGuzman M.D., Chief Medical Officer (Age 53)
  • Mr. Shaun M. O'Neil, Chief Commercial Officer

Who are PAVmed's major shareholders?

PAVmed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc (1.40%) and Vanguard Group Inc. (1.40%). Company insiders that own PAVmed stock include Dennis M Mcgrath, Ira Scott Greenspan and Lishan Aklog. View Institutional Ownership Trends for PAVmed.

Which major investors are buying PAVmed stock?

PAVM stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc and Vanguard Group Inc.. Company insiders that have bought PAVmed stock in the last two years include Dennis M Mcgrath and Lishan Aklog. View Insider Buying and Selling for PAVmed.

How do I buy shares of PAVmed?

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PAVmed's stock price today?

One share of PAVM stock can currently be purchased for approximately $1.0636.

How big of a company is PAVmed?

PAVmed has a market capitalization of $28.40 million. The company earns $-9,510,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. PAVmed employs 5 workers across the globe.

What is PAVmed's official website?

The official website for PAVmed is

How can I contact PAVmed?

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected]

MarketBeat Community Rating for PAVmed (NASDAQ PAVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about PAVmed and other stocks. Vote "Outperform" if you believe PAVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel